Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15621612 | 0.70 | HDAC4 (0.43) | ACHEHCAR2HDAC4MEN1KMT2A | |
| SCHEMBL8207862 | 0.70 | ACHE (0.39) | ACHEHCAR2HDAC4MEN1KMT2A | |
| SCHEMBL7713927 | 0.68 | HCAR2 (0.38) | ACHEHCAR2MEN1KMT2APGR | |
| SCHEMBL5403636 | 0.67 | HTR2A (0.37) | PDK2 | |
| SCHEMBL5403647 | 0.67 | HTR2A (0.37) | PDK2 | |
| SCHEMBL5403641 | 0.67 | HTR2A (0.37) | PDK2 | |
| SCHEMBL8766307 | 0.67 | HDAC4 (0.38) | HDAC4MEN1KMT2ABACE1CYP2C9 | |
| SCHEMBL17673207 | 0.67 | BACE1 (0.40) | ACHEHCAR2HDAC4MEN1KMT2A | |
| SCHEMBL256776 | 0.67 | HDAC4 (0.44) | ACHEHCAR2HDAC4KDM1A | |
| SCHEMBL12203839 | 0.67 | HDAC4 (0.49) | HCAR2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056022-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056022-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | ACHE 4019/4885HCAR2 4227/4885HDAC4 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.